145 related articles for article (PubMed ID: 14652283)
1. Serum enterolactone concentration is not associated with prostate cancer risk in a nested case-control study.
Kilkkinen A; Virtamo J; Virtanen MJ; Adlercreutz H; Albanes D; Pietinen P
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1209-12. PubMed ID: 14652283
[TBL] [Abstract][Full Text] [Related]
2. Serum enterolactone concentration and the risk of coronary heart disease in a case-cohort study of Finnish male smokers.
Kilkkinen A; Erlund I; Virtanen MJ; Alfthan G; Ariniemi K; Virtamo J
Am J Epidemiol; 2006 Apr; 163(8):687-93. PubMed ID: 16510545
[TBL] [Abstract][Full Text] [Related]
3. Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study.
Kilkkinen A; Virtamo J; Vartiainen E; Sankila R; Virtanen MJ; Adlercreutz H; Pietinen P
Int J Cancer; 2004 Jan; 108(2):277-80. PubMed ID: 14639615
[TBL] [Abstract][Full Text] [Related]
4. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland.
Pietinen P; Stumpf K; Männistö S; Kataja V; Uusitupa M; Adlercreutz H
Cancer Epidemiol Biomarkers Prev; 2001 Apr; 10(4):339-44. PubMed ID: 11319174
[TBL] [Abstract][Full Text] [Related]
5. Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the cancer prostate Sweden study (Sweden).
Hedelin M; Klint A; Chang ET; Bellocco R; Johansson JE; Andersson SO; Heinonen SM; Adlercreutz H; Adami HO; Grönberg H; Bälter KA
Cancer Causes Control; 2006 Mar; 17(2):169-80. PubMed ID: 16425095
[TBL] [Abstract][Full Text] [Related]
6. Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study.
Stattin P; Adlercreutz H; Tenkanen L; Jellum E; Lumme S; Hallmans G; Harvei S; Teppo L; Stumpf K; Luostarinen T; Lehtinen M; Dillner J; Hakama M
Int J Cancer; 2002 May; 99(1):124-9. PubMed ID: 11948503
[TBL] [Abstract][Full Text] [Related]
7. Enterolactone is differently associated with estrogen receptor beta-negative and -positive breast cancer in a Swedish nested case-control study.
Sonestedt E; Borgquist S; Ericson U; Gullberg B; Olsson H; Adlercreutz H; Landberg G; Wirfält E
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3241-51. PubMed ID: 18990767
[TBL] [Abstract][Full Text] [Related]
8. Plasma enterolactone and breast cancer incidence by estrogen receptor status.
Olsen A; Knudsen KE; Thomsen BL; Loft S; Stripp C; Overvad K; Møller S; Tjønneland A
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2084-9. PubMed ID: 15598765
[TBL] [Abstract][Full Text] [Related]
9. Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study.
Vanharanta M; Voutilainen S; Lakka TA; van der Lee M; Adlercreutz H; Salonen JT
Lancet; 1999 Dec 18-25; 354(9196):2112-5. PubMed ID: 10609816
[TBL] [Abstract][Full Text] [Related]
10. Plasma enterolactone and genistein and the risk of premenopausal breast cancer.
Piller R; Chang-Claude J; Linseisen J
Eur J Cancer Prev; 2006 Jun; 15(3):225-32. PubMed ID: 16679865
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of plasma enterolactone and prostate cancer risk (Sweden).
Stattin P; Bylund A; Biessy C; Kaaks R; Hallmans G; Adlercreutz H
Cancer Causes Control; 2004 Dec; 15(10):1095-102. PubMed ID: 15801493
[TBL] [Abstract][Full Text] [Related]
12. Risk of cardiovascular disease-related and all-cause death according to serum concentrations of enterolactone: Kuopio Ischaemic Heart Disease Risk Factor Study.
Vanharanta M; Voutilainen S; Rissanen TH; Adlercreutz H; Salonen JT
Arch Intern Med; 2003 May; 163(9):1099-104. PubMed ID: 12742810
[TBL] [Abstract][Full Text] [Related]
13. An incident case-referent study on plasma enterolactone and breast cancer risk.
Hultén K; Winkvist A; Lenner P; Johansson R; Adlercreutz H; Hallmans G
Eur J Nutr; 2002 Aug; 41(4):168-76. PubMed ID: 12242585
[TBL] [Abstract][Full Text] [Related]
14. Fatty acids and risk of prostate cancer in a nested case-control study in male smokers.
Männistö S; Pietinen P; Virtanen MJ; Salminen I; Albanes D; Giovannucci E; Virtamo J
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1422-8. PubMed ID: 14693732
[TBL] [Abstract][Full Text] [Related]
15. Phyto-oestrogens and risk of prostate cancer in Scottish men.
Heald CL; Ritchie MR; Bolton-Smith C; Morton MS; Alexander FE
Br J Nutr; 2007 Aug; 98(2):388-96. PubMed ID: 17403269
[TBL] [Abstract][Full Text] [Related]
16. Plasma enterolignans are associated with lower colorectal adenoma risk.
Kuijsten A; Arts IC; Hollman PC; van't Veer P; Kampman E
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1132-6. PubMed ID: 16775171
[TBL] [Abstract][Full Text] [Related]
17. Changes in serum enterolactone, genistein, and daidzein in a dietary intervention study in Finland.
Stumpf K; Pietinen P; Puska P; Adlercreutz H
Cancer Epidemiol Biomarkers Prev; 2000 Dec; 9(12):1369-72. PubMed ID: 11142423
[TBL] [Abstract][Full Text] [Related]
18. Determinants of serum enterolactone concentration.
Kilkkinen A; Stumpf K; Pietinen P; Valsta LM; Tapanainen H; Adlercreutz H
Am J Clin Nutr; 2001 Jun; 73(6):1094-100. PubMed ID: 11382665
[TBL] [Abstract][Full Text] [Related]
19. Variation in fasting and non-fasting serum enterolactone concentrations in women of the Malmö Diet and Cancer cohort.
Sonestedt E; Ericson U; Gullberg B; Peñalvo JL; Adlercreutz H; Wirfält E
Eur J Clin Nutr; 2008 Aug; 62(8):1005-9. PubMed ID: 17538540
[TBL] [Abstract][Full Text] [Related]
20. Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study.
Guglielmini P; Rubagotti A; Boccardo F
Breast Cancer Res Treat; 2012 Apr; 132(2):661-8. PubMed ID: 22094938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
